Association between CYP2D6 genotype and tamoxifen-induced hot flashes in a prospective cohort

N. Lynn Henry, James M. Rae, Lang Li, Faouzi Azzouz, Todd C. Skaar, Zereunesay Desta, Matthew J. Sikora, Santosh Philips, Anne T. Nguyen, Anna Maria Storniolo, Daniel F. Hayes, David A. Flockhart, Vered Stearns

Research output: Contribution to journalArticlepeer-review

Abstract

Women with reduced CYP2D6 activity have low endoxifen concentrations and likely worse long term benefits from tamoxifen. We investigated the association between CYP2D6 genotype and tamoxifen-induced hot flashes in a prospective cohort. We collected hot flash frequency and severity data over 12 months from 297 women initiating tamoxifen. We performed CYP2D6 genotyping using the AmpliChip CYP450 test and correlated inherited genetic polymorphisms in CYP2D6 and tamoxifen-induced hot flashes. Intermediate metabolizers had greater mean hot flash scores after 4 months of tamoxifen therapy (44.3) compared to poor metabolizers (20.6, P = 0.038) or extensive metabolizers (26.9, P = 0.011). At 4 months, we observed a trend toward fewer severe hot flashes in poor metabolizers compared to intermediate plus extensive metabolizers (P = 0.062). CYP2D6 activity may be a modest predictive factor for tamoxifen-induced hot flashes. The presence or absence of hot flashes should not be used to determine tamoxifen's efficacy.

Original languageEnglish (US)
Pages (from-to)571-575
Number of pages5
JournalBreast Cancer Research and Treatment
Volume117
Issue number3
DOIs
StatePublished - Jan 21 2009

Keywords

  • Breast cancer
  • CYP2D6
  • Genotype
  • Hot flash
  • Tamoxifen

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Association between CYP2D6 genotype and tamoxifen-induced hot flashes in a prospective cohort'. Together they form a unique fingerprint.

Cite this